Scancell Holdings plc (LON:SCLP – Get Rating) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 18.57 ($0.23) and traded as low as GBX 16.45 ($0.20). Scancell shares last traded at GBX 17 ($0.21), with a volume of 315,138 shares.
Scancell Price Performance
The business has a fifty day moving average of GBX 20.26 and a 200-day moving average of GBX 18.57. The company has a current ratio of 11.45, a quick ratio of 13.01 and a debt-to-equity ratio of 61.41. The firm has a market cap of £139.13 million, a PE ratio of -1,700.00 and a beta of 0.61.
Scancell Company Profile
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers.
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.